{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:41:14Z","timestamp":1791844874885,"version":"4.3.4"},"reference-count":55,"publisher":"American Society for Clinical Investigation","issue":"6","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,22]]},"abstract":"<jats:p>\n                    Malignant pleural effusion (MPE) is an incurable common manifestation of many malignancies. Its formation is orchestrated by complex interactions among tumor cells, inflammatory cells, and the vasculature. Tumor-associated macrophages present the dominant inflammatory population of MPE, and M2 macrophage numbers account for dismal prognosis. M2 polarization is known to be triggered by CSF1\/CSF1 receptor (CSF1R) signaling. We hypothesized that CSF1R\n                    <jats:sup>+<\/jats:sup>\n                    M2 macrophages favor MPE formation and could be therapeutically targeted to limit MPE. We generated mice with CSF1R-deficient macrophages and induced lung and colon adenocarcinoma\u2013associated MPE. We also examined the therapeutic potential of a clinically relevant CSF1R inhibitor (BLZ945) in lung and colon adenocarcinoma\u2013induced experimental MPE. We showed that CSF1R\n                    <jats:sup>+<\/jats:sup>\n                    macrophages promoted pleural fluid accumulation by enhancing vascular permeability, destabilizing tumor vessels, and favoring immune suppression. We also showed that CSF1R inhibition limited MPE in vivo by reducing vascular permeability and neoangiogenesis and impeding tumor progression. This was because apart from macrophages, CSF1R signals in cancer-associated fibroblasts leading to macrophage inflammatory protein 2 secretion triggered the manifestation of suppressive and angiogenic properties in macrophages upon CXCR2 paracrine activation. Pharmacological targeting of the CSF1\/CSF1R axis can therefore be a vital strategy for limiting MPE.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.155300","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T14:00:57Z","timestamp":1647871257000},"source":"Crossref","is-referenced-by-count":19,"title":["CSF1\/CSF1R signaling mediates malignant pleural effusion formation"],"prefix":"10.1172","volume":"7","author":[{"given":"Chrysavgi N.","family":"Kosti","sequence":"first","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Photene C.","family":"Vaitsi","sequence":"additional","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5763","authenticated-orcid":true,"given":"Apostolos G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianthi P.","family":"Iliopoulou","sequence":"additional","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherina K.","family":"Psarra","sequence":"additional","affiliation":[{"name":"Department of Immunology \u2014 Histocompatibility, Evangelismos Hospital, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7143-3311","authenticated-orcid":true,"given":"Sophia F.","family":"Magkouta","sequence":"additional","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis T.","family":"Kalomenidis","sequence":"additional","affiliation":[{"name":"Marianthi Simou Laboratory, 1st Department of Critical Care and Pulmonary Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1415ST"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0465PP"},{"issue":"4","key":"B4","first-page":"279","article-title":"Macrophages in malignant pleural effusions \u2014 alternatively activated tumor associated macrophages","volume":"16","author":"Kaczmarek","year":"2012","journal-title":"Contemp Oncol (Pozn)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1701-9"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/dvg.20219"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3547"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1196"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front Physiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2327"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.021"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000182"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1227"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.10.005"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1370455"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01835"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0257-y"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00506-6"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature13862"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.169"},{"issue":"5","key":"B24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00262-020-02781-8","article-title":"The M1\/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer","volume":"70","author":"Wu","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307592"},{"issue":"11","key":"B26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120631","article-title":"Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy","volume":"3","author":"Gyori","year":"2018","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8274.CD-10-0028"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26968"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.03.038"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112546"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021857"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3337"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0866"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.261"},{"issue":"10","key":"B35","article-title":"More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis","volume":"13","author":"Gschwandtner","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3723"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1912"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0435-6"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01536-0"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0309"},{"issue":"8","key":"B41","first-page":"4587","article-title":"Better clinical efficiency of TILs for malignant pleural effusion and ascites than cisplatin through intrapleural and intraperitoneal infusion","volume":"37","author":"Chu","year":"2017","journal-title":"Anticancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0590-4"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2973"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.65"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14745"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1401s83","article-title":"The isolation and characterization of murine macrophages","volume":"83","author":"Zhang","year":"2008","journal-title":"Curr Protoc Immunol"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4825108","article-title":"Isolation of fibroblast-activation protein-specific cancer-associated fibroblasts","volume":"2017","author":"Huang","year":"2017","journal-title":"Biomed Res Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008942828960"},{"issue":"8","key":"B50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071207","article-title":"Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion","volume":"14","author":"Marazioti","year":"2013","journal-title":"PLoS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0130OC"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7912"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000835"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12604"},{"issue":"12","key":"B55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134885","article-title":"MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage","volume":"5","author":"Magkouta","year":"2020","journal-title":"JCI Insight"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/155300\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:37:06Z","timestamp":1779147426000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/155300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,22]]},"published-print":{"date-parts":[[2022,3,22]]}},"alternative-id":["10.1172\/jci.insight.155300"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.155300","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"e155300"}}